XENETIC BIOSCIENCES, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount
XENETIC BIOSCIENCES, INC. (XBIO) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount of $6.50 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-18.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2025-03-18
- XENETIC BIOSCIENCES, INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2024 was $6.50K, a 9.95% decline from fiscal 2023.
- XENETIC BIOSCIENCES, INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2023 was $7.21K, a 62.21% decline from fiscal 2022.
- XENETIC BIOSCIENCES, INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2022 was $19.09K, a 28.73% increase from fiscal 2021.
- XENETIC BIOSCIENCES, INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2021 was $14.83K, a 33.41% decline from fiscal 2020.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount 12 month |
|---|---|
| 2024-12-31 | $6.50K 10-K · filed 2025-03-18 |
| 2023-12-31 | $7.21K 10-K · filed 2025-03-18 |
| 2022-12-31 | $19.09K 10-K · filed 2024-03-21 |
| 2021-12-31 | $14.83K 10-K · filed 2023-03-22 |
| 2020-12-31 | $22.27K 10-K · filed 2022-03-22 |
| 2019-12-31 | $11.08K 10-K · filed 2021-03-16 |
| 2018-12-31 | $20.44K 10-K · filed 2020-03-26 |
| 2017-12-31 | -$22.09K 10-K · filed 2019-03-29 |
| 2016-12-31 | $524.13K 10-K · filed 2018-03-30 |
| 2015-12-31 | $308.89K 10-K · filed 2017-03-31 |
| 2014-12-31 | $505.04K 10-K · filed 2016-03-30 |
| 2013-12-31 | $9.18K 10-K · filed 2015-07-20 |
| 2012-12-31 | $6.77K 10-K · filed 2015-07-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |